Dr. Small-Howard explains the mechanisms for the treatment of chronic and neuropathic pain using proprietary, cannabis-based formulations
LAS VEGAS, Oct. 9, 2018 /PRNewswire/ -- GB Sciences, Inc. (OTCQB: GBLX) announces that their Chief Science Officer, Dr. Andrea Small-Howard (http://www.cannmedevents.com/andrea-small-howard/), will be presenting the results of GB Sciences' novel pain formulation research project during the poster session for CannMed 2018 to be held at the UCLA Luskin Conference Center from October 22nd to October 24th.
According to the conference organizers, "CannMed 2018 is a gathering of the greatest minds in medical cannabis, where they will further the convergence of medical cannabis research, treatment, and product development. The world's top medical cannabis researchers will present their latest findings with regards to the efficacy of treating a variety of conditions with cannabis. Clinicians will share compelling case studies and clinical pearls they have collected through their experience treating patients with cannabis. Cannabis industry leaders will also share how they are adopting innovative testing methods and technologies to create new products that move the industry forward."
"CannMed 2018 is the perfect venue for sharing the scientific research supporting our proprietary, cannabis-based formulations for the treatment of chronic and neuropathic pain because of the superb academic and clinical credentials of the presenters and attendees at CannMed," said Dr. Small-Howard. "GB Sciences will further be presenting information on its medical cannabis product lines in booth 202. These products are designed to be sold in Nevada and Louisiana. We hope that interested participants will visit us!"
John Poss, CEO and Chairman of GB Sciences said "We are proud to be a part of CannMed 2018. In gathering all these impressive scientists, researchers and inventors, we celebrate the future of healing. This is the inspiration for GB Sciences."
About GB Sciences, Inc.
GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company's goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.
Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Note: Although the Company's research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.
Contact Information
Corporate:
GB Sciences, Inc., 3550 West Teco Ave., Las Vegas, NV 89118
866-721-0297, or
Tom Arcuragi, EVP, tom@gbsciences.com
SOURCE GB Sciences, Inc.
